CAR-T therapy is the most clinically advanced application of synthetic biology in medicine and has fundamentally changed the treatment of certain blood cancers. A CAR is a synthetic protein that combines an extracellular antigen-binding domain (typically derived from an antibody) with intracellular signaling domains that activate T cell killing and proliferation. When expressed in a patient's T cells, the CAR directs them to recognize and destroy cancer cells bearing the target antigen. The FDA approved the first two CAR-T products, Kymriah (Novartis) and Yescarta (Gilead/Kite), in 2017, and several additional products have since reached the market.
The engineering of next-generation CARs draws heavily on synthetic biology principles. ArsenalBio uses high-throughput CRISPR screening to identify gene edits that enhance CAR-T function, integrating CAR constructs at specific genomic loci for more consistent expression. Researchers are developing logic-gated CARs that require recognition of multiple antigens before activating, reducing the risk of off-tumor toxicity. Switchable CARs that can be turned on and off with small molecules, and armored CARs that secrete cytokines or checkpoint inhibitors in the tumor microenvironment, represent further applications of gene circuit design principles to cancer immunotherapy.
Despite remarkable clinical results in B-cell malignancies, CAR-T therapy faces significant challenges. Manufacturing is complex and expensive, with each treatment costing $300,000 to $500,000. Solid tumors present additional obstacles including antigen heterogeneity, physical barriers to T cell infiltration, and immunosuppressive microenvironments. Companies like Poseida Therapeutics, Arcellx, and Umoja Biopharma are developing solutions including non-viral CAR delivery, novel binding domains, and in vivo CAR generation where the engineering occurs inside the patient's body rather than in a manufacturing facility.